29th February 2012
Simbec – Celebrating Long Term Expertise
Whilst the needs and challenges for sponsors continue to evolve (be they financial constraints, regulatory changes or scientific complexities) one constant solution through all this turmoil remains Simbec’s customised approach to meet specific challenges.
For over 35 years Simbec has been providing customised solutions to the needs of our Sponsors helping them to reshape their business models and bring practical solutions to early-stage programs.
Dr. Salvatore Febbraro, the Chief Medical Officer of Altasciences’ operations, (Simbec Research in the UK and Algorithme Pharma in Canada), is based at Simbec and has been the Chief Investigator for over 100 First-in-Human clinical trials and over 300 other early phase research projects of ranging from small molecule therapeutics to biologicals (including protein therapeutics, nanoparticles, vaccines, antibodies, and gene and immunoactive therapeutics).
Recent early clinical studies include drugs targeted for diabetes/obesity, neurodegenerative disease (in particular MS & Parkinsons), orphan drugs for unmet medical needs, respiratory disease (Asthma, COPD & CF), novel anti-infectives and anti-inflammatories.
Simbec, first established in 1976, has provided continuous services in early drug development focussing on Phase I to Phase IIa Clinical Research Services of investigational medicinal products (IMPs) for pharmaceutical and biotechnology companies. Simbec is a full service early phase CRO, supplementary accredited for Phase 1 by the MHRA. We look forward to the next 35 years and adapting to the inevitable challenges ahead.
To learn more about our services,
contact us at: contact@simbec.co.uk